• Patchliner

    Most versatile automated patch clamp system on the market
  • Patchliner

    In-house production and QC of consumables
  • Patchliner

    More than 10 years experience in assay design and support
  • Patchliner

    All features & benefits of manual patch clamp
  • Patchliner

    More than 100 Patchliners sold worldwide

2018 - Introducing simulated IK1 into human iPSC-cardiomyocytes using dynamic clamp on an automated patch clamp setup

icon pl   Patchliner poster, Biophysics Annual Meeting 2018  logo pdf   (1.0 MB)

Abstract:

Dynamic clamp is a powerful tool involving injection of real-time simulated membrane currents into patch clamped cells. This technique has been employed in conventional patch clamp electrophysiology to introduce inward rectifier IK1 current into human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). IK1 is expressed at low levels in these cells. For this reason, hiPSC-CMs display a more depolarized membrane potential than adult cardiomyocytes, limiting their use in safety pharmacology. Therefore, introducing simulated IK1 into hiPSCCMs may improve maturity of these cells and ensure that they represent a viable alternative to the scarcely available dissociated adult human cardiomyocytes. Indeed, they are attractive cells types because of their unlimited availability and human origin.

In this study, we combined dynamic clamp with an automated patch clamp platform to demonstrate that IK1 conductance can be added to hiPSC-CMs on this platform. Our results
show that IK1 can be successfully added to hiPSC-CMs to up to 4 cells simultaneously and that this results in a more stabilized and hyperpolarized resting membrane potential. Action potential (AP) shape also changes when IK1 is added. We have used with different amounts of IK1 (100-2000 pS/pF) and show that increasing IK1 results in AP shortening and an acceleration of the upstroke. We could measure native Ba2+-sensitive IK1 in voltage clamp mode in approximately 50% of these cells, but IK1 was small, on average 1.98±0.42 pA/pF (mean ± SEM). Adding a Ca2+ channel activator (BayK 8644), or blocker (nifedipine) caused an increase and decrease of the AP duration, respectively. In conclusion, combining dynamic clamp with automated patch clamping results in an enhanced, medium-throughput platform for safety pharmacology.

Back to Overview

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok